Lifeloc Technologies, Inc. reported financial results for the fiscal year ended December 31, 2025, announcing 6% revenue growth to $9.027 million. The company disclosed a net loss of $2.470 million, significantly impacted by a non-cash deferred tax valuation allowance charge of $1.738 million.
Key takeaways
Revenue increased 6% to $9.027 million for the year ended December 31, 2025, compared to $8.538 million in 2024.
Net loss widened to $2.470 million, or $0.90 per diluted share, compared to a net loss of $1.053 million, or $0.41 per diluted share, in 2024.
A non-cash charge of $1.738 million was recorded for increased valuation allowance for deferred taxes in 2025, up from $187 thousand in 2024.
Gross margin remained stable at 40.3% for 2025 compared to 40.4% for 2024.
Cash and cash equivalents decreased to $746,001 as of December 31, 2025, from $1,243,746 at the end of 2024.
The company reported progress on its SpinDetect™ Centrifugal Drug Analyzer, with production mold fabrication targeted for Q1 2026.